Coversin

Drug Profile

Coversin

Alternative Names: Coversin; EV 576; PAS-coversin; rEV 576

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evolutec
  • Developer Akari Therapeutics; Evolutec
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Guillain-Barre syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Preclinical Bullous pemphigoid; Conjunctivitis; Myasthenia gravis; Sjogren's syndrome
  • No development reported Guillain-Barre syndrome
  • Discontinued Asthma; Autoimmune disorders; Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Guillain-Barre-syndrome in Switzerland (SC, Injection)
  • 11 Oct 2017 Interim efficacy data from the phase II COBALT trial in Paroxysmal nocturnal haemoglobinuria released by Akari Therapeutics
  • 21 Sep 2017 Akari Therapeutics announces intention to submit NDA to US FDA and MAA to EMA for Paroxysmal nocturnal hemoglobinuria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top